Antisense Therapeutics trial of ATL1101 in prostate cancer shows promise Antisense Therapeutics Ltd.

Tumor cells build level of resistance to chemotherapy treatment via survival mechanisms that consist of IGF-I signaling. Inside our prostate cancers model we have shown that ATL1101, which can be an IGF-I receptor blocker, can inhibit this system and restore sensitivity to chemotherapy. ANP is in dialogue with several parties regarding the continued advancement of ATL1101 in prostate cancer, looking to build on ATL1101’s robust pre-clinical pharmacology data bundle, completed mouse toxicology research, established drug manufacturing procedure and strong intellectual house protection..The integrated E/Stage – ED PulseCheck solution supplies the most satisfactory clinical information and income management solution designed for the ED. E/Stage uses documentation obtainable in ED PulseCheck to calculate constant and defensible facility check out levels, capture and code these billable solutions and submit the fees to the billing program. Hospital charge details is linked and gathered to specific procedures, assessments and orders, leading to faster, even more accurate billing. Additionally, E/Point communicates straight with clinicians if an individual chart requires extra documentation.